Stock Market Reviews

OLMA (Olema Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on OLMA (Olema Pharmaceuticals, Inc.). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Pfizer (PFE) Partners With Olema For New Metastatic Breast Cancer Study
  Pfizer (PFE) recently made headlines with Olema Pharmaceuticals announcing a significant clinical trial collaboration, enhancing their portfolio in the treatment of metastatic breast cancer. Over the last quarter, Pfizer's stock moved up by 7%, aligning with broader market trends. This increase may have been driven by the improved Q2 2025 earnings report, which showed significant revenue and net income growth. Additionally, product innovations like the new COVID-19 vaccine approval with...
  Sep 3, 2025 - $OLMA
• Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
  Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline metastatic breast cancer setting SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for bre
  Sep 2, 2025 - $OLMA
• Clinical Trial Progress and Analyst Endorsement Spark Short-Term Rebound for Olema Pharmaceuticals
  Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the 11 Best Short-Term Stocks to Invest in. The company sees its Buy rating reiterated following promising results from its clinical trials, including the VERITAC-2 trial. Headquartered in California, Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for women’s cancers. […]
  Aug 13, 2025 - $OLMA
• Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
  Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclibOPERA-01 enrollment ongoing with top-line data expected in the second half of 2026; OPERA-02 on track to initiate in Q3 2025Mature data from the Phase 1b/2 study of palazestrant in combination with ribociclib to be presented at ESMO 2025 Ended the second quarter with $361.9 million in cash, cash equivalents, and marketable securities SAN FRA
  Aug 11, 2025 - $OLMA
• Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
  90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclibOPERA-01 trial-in-progress poster to be presented on Monday, June 2 between 9:00am–12:00pm CT / 10:00am–1:00pm ET SAN FRANCISCO, May 28, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of
  May 28, 2025 - $OLMA
• Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?
  The consensus price target hints at a 386.4% upside potential for Olema Pharmaceuticals (OLMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
  May 21, 2025 - $OLMA
• Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
  Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
  May 15, 2025 - $OLMA
• Olema Oncology Reports First Quarter 2025 Financial and Operating Results
  Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported by promising updated efficacy data from ongoing Phase 1b/2 studyPivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in 2/3L metastatic breast cancer continues to advance with top-line data anticipated in 2026; trial-in-progress poster to be highlighted at ASCO Annual MeetingPreclinical data for OP-3136 presented at AACR demonstratin
  May 13, 2025 - $OLMA